This is in line with recent studies showing that AP-1 (and other TFs) re-organizes enhancer landscapes resulting in transcriptional transitions that promote tumour phenotypic plasticity and resistance to Tamoxifen (an ER modulator) (65). Here, FOS is linked to neoplasm.